LIGAND PHARMACEUTICALS (LGND) Stock Fundamental Analysis

NASDAQ:LGND • US53220K5048

202.55 USD
+4.24 (+2.14%)
At close: Mar 2, 2026
202.55 USD
0 (0%)
After Hours: 3/2/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to LGND. LGND was compared to 193 industry peers in the Pharmaceuticals industry. While LGND has a great profitability rating, there are some minor concerns on its financial health. LGND has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year LGND was profitable.
  • LGND had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: LGND reported negative net income in multiple years.
  • LGND had a positive operating cash flow in 4 of the past 5 years.
LGND Yearly Net Income VS EBIT VS OCF VS FCFLGND Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

  • LGND's Return On Assets of 3.29% is amongst the best of the industry. LGND outperforms 83.42% of its industry peers.
  • LGND's Return On Equity of 5.11% is amongst the best of the industry. LGND outperforms 83.94% of its industry peers.
  • The Return On Invested Capital of LGND (1.58%) is better than 79.27% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for LGND is significantly below the industry average of 12.91%.
  • The last Return On Invested Capital (1.58%) for LGND is above the 3 year average (1.12%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 3.29%
ROE 5.11%
ROIC 1.58%
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)1.12%
ROIC(5y)1.78%
LGND Yearly ROA, ROE, ROICLGND Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

1.3 Margins

  • Looking at the Profit Margin, with a value of 19.34%, LGND belongs to the top of the industry, outperforming 91.19% of the companies in the same industry.
  • Looking at the Operating Margin, with a value of 11.48%, LGND belongs to the top of the industry, outperforming 84.97% of the companies in the same industry.
  • In the last couple of years the Operating Margin of LGND has declined.
  • The Gross Margin of LGND (94.27%) is better than 96.37% of its industry peers.
  • LGND's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 11.48%
PM (TTM) 19.34%
GM 94.27%
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
LGND Yearly Profit, Operating, Gross MarginsLGND Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 200 300 400 500

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • LGND has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • There is no outstanding debt for LGND. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LGND Yearly Shares OutstandingLGND Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
LGND Yearly Total Debt VS Total AssetsLGND Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

  • An Altman-Z score of 5.82 indicates that LGND is not in any danger for bankruptcy at the moment.
  • LGND has a Altman-Z score of 5.82. This is in the better half of the industry: LGND outperforms 77.72% of its industry peers.
  • The Debt to FCF ratio of LGND is 14.48, which is on the high side as it means it would take LGND, 14.48 years of fcf income to pay off all of its debts.
  • With a decent Debt to FCF ratio value of 14.48, LGND is doing good in the industry, outperforming 78.76% of the companies in the same industry.
  • LGND has a Debt/Equity ratio of 0.47. This is a healthy value indicating a solid balance between debt and equity.
  • LGND has a worse Debt to Equity ratio (0.47) than 60.62% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF 14.48
Altman-Z 5.82
ROIC/WACC0.17
WACC9.1%
LGND Yearly LT Debt VS Equity VS FCFLGND Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

  • LGND has a Current Ratio of 24.69. This indicates that LGND is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 24.69, LGND belongs to the top of the industry, outperforming 94.30% of the companies in the same industry.
  • LGND has a Quick Ratio of 24.30. This indicates that LGND is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 24.30, LGND belongs to the top of the industry, outperforming 93.26% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 24.69
Quick Ratio 24.3
LGND Yearly Current Assets VS Current LiabilitesLGND Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • LGND shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.81%, which is quite impressive.
  • LGND shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 12.06% yearly.
EPS 1Y (TTM)40.81%
EPS 3Y23.39%
EPS 5Y12.06%
EPS Q2Q%59.06%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%39.37%

3.2 Future

  • The Earnings Per Share is expected to grow by 12.89% on average over the next years. This is quite good.
  • Based on estimates for the next years, LGND will show a quite strong growth in Revenue. The Revenue will grow by 15.13% on average per year.
EPS Next Y5.22%
EPS Next 2Y10.46%
EPS Next 3Y12.15%
EPS Next 5Y12.89%
Revenue Next Year9.77%
Revenue Next 2Y13.73%
Revenue Next 3Y15.21%
Revenue Next 5Y15.13%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
LGND Yearly Revenue VS EstimatesLGND Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
LGND Yearly EPS VS EstimatesLGND Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 25.19, which means the current valuation is very expensive for LGND.
  • Based on the Price/Earnings ratio, LGND is valued a bit cheaper than the industry average as 79.79% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 27.13, LGND is valued at the same level.
  • LGND is valuated rather expensively with a Price/Forward Earnings ratio of 23.94.
  • Based on the Price/Forward Earnings ratio, LGND is valued a bit cheaper than the industry average as 76.17% of the companies are valued more expensively.
  • LGND is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 28.11, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 25.19
Fwd PE 23.94
LGND Price Earnings VS Forward Price EarningsLGND Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of LGND indicates a somewhat cheap valuation: LGND is cheaper than 77.72% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, LGND is valued a bit cheaper than the industry average as 76.17% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 129.59
EV/EBITDA 50.11
LGND Per share dataLGND EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • LGND has a very decent profitability rating, which may justify a higher PE ratio.
  • LGND's earnings are expected to grow with 12.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.83
PEG (5Y)2.09
EPS Next 2Y10.46%
EPS Next 3Y12.15%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for LGND!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LIGAND PHARMACEUTICALS

NASDAQ:LGND (3/2/2026, 8:00:02 PM)

After market: 202.55 0 (0%)

202.55

+4.24 (+2.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners106.73%
Inst Owner Change-42.5%
Ins Owners1.62%
Ins Owner Change1.93%
Market Cap3.99B
Revenue(TTM)N/A
Net Income(TTM)48.58M
Analysts85.71
Price Target248.31 (22.59%)
Short Float %6.67%
Short Ratio5.87
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.83%
Min EPS beat(2)10.36%
Max EPS beat(2)57.31%
EPS beat(4)4
Avg EPS beat(4)19.98%
Min EPS beat(4)4.63%
Max EPS beat(4)57.31%
EPS beat(8)8
Avg EPS beat(8)37.45%
EPS beat(12)12
Avg EPS beat(12)53.58%
EPS beat(16)15
Avg EPS beat(16)61.91%
Revenue beat(2)2
Avg Revenue beat(2)25.66%
Min Revenue beat(2)6.44%
Max Revenue beat(2)44.89%
Revenue beat(4)4
Avg Revenue beat(4)18.43%
Min Revenue beat(4)6.44%
Max Revenue beat(4)44.89%
Revenue beat(8)8
Avg Revenue beat(8)17.31%
Revenue beat(12)11
Avg Revenue beat(12)12.65%
Revenue beat(16)14
Avg Revenue beat(16)16.25%
PT rev (1m)0%
PT rev (3m)6.72%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.6%
EPS NY rev (1m)0%
EPS NY rev (3m)10.42%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.36%
Revenue NY rev (1m)0%
Revenue NY rev (3m)12.73%
Valuation
Industry RankSector Rank
PE 25.19
Fwd PE 23.94
P/S 15.87
P/FCF 129.59
P/OCF 124.9
P/B 4.2
P/tB 9.75
EV/EBITDA 50.11
EPS(TTM)8.04
EY3.97%
EPS(NY)8.46
Fwd EY4.18%
FCF(TTM)1.56
FCFY0.77%
OCF(TTM)1.62
OCFY0.8%
SpS12.77
BVpS48.28
TBVpS20.77
PEG (NY)4.83
PEG (5Y)2.09
Graham Number93.46
Profitability
Industry RankSector Rank
ROA 3.29%
ROE 5.11%
ROCE 1.99%
ROIC 1.58%
ROICexc 2.92%
ROICexgc 9.48%
OM 11.48%
PM (TTM) 19.34%
GM 94.27%
FCFM 12.24%
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)1.12%
ROIC(5y)1.78%
ROICexc(3y)1.91%
ROICexc(5y)2.67%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)1.42%
ROCE(5y)2.25%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-16.87%
ROICexc growth 5YN/A
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
F-Score5
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF 14.48
Debt/EBITDA 7.07
Cap/Depr 3.38%
Cap/Sales 0.46%
Interest Coverage 96.15
Cash Conversion 50.63%
Profit Quality 63.32%
Current Ratio 24.69
Quick Ratio 24.3
Altman-Z 5.82
F-Score5
WACC9.1%
ROIC/WACC0.17
Cap/Depr(3y)71.95%
Cap/Depr(5y)50.12%
Cap/Sales(3y)19.71%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.81%
EPS 3Y23.39%
EPS 5Y12.06%
EPS Q2Q%59.06%
EPS Next Y5.22%
EPS Next 2Y10.46%
EPS Next 3Y12.15%
EPS Next 5Y12.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%39.37%
Revenue Next Year9.77%
Revenue Next 2Y13.73%
Revenue Next 3Y15.21%
Revenue Next 5Y15.13%
EBIT growth 1Y64.02%
EBIT growth 3Y-33.67%
EBIT growth 5YN/A
EBIT Next Year674.52%
EBIT Next 3Y155.59%
EBIT Next 5Y79.19%
FCF growth 1Y-61.26%
FCF growth 3Y10.8%
FCF growth 5YN/A
OCF growth 1Y-66.41%
OCF growth 3Y7.19%
OCF growth 5YN/A

LIGAND PHARMACEUTICALS / LGND FAQ

What is the ChartMill fundamental rating of LIGAND PHARMACEUTICALS (LGND) stock?

ChartMill assigns a fundamental rating of 5 / 10 to LGND.


What is the valuation status of LIGAND PHARMACEUTICALS (LGND) stock?

ChartMill assigns a valuation rating of 4 / 10 to LIGAND PHARMACEUTICALS (LGND). This can be considered as Fairly Valued.


How profitable is LIGAND PHARMACEUTICALS (LGND) stock?

LIGAND PHARMACEUTICALS (LGND) has a profitability rating of 7 / 10.


What is the financial health of LIGAND PHARMACEUTICALS (LGND) stock?

The financial health rating of LIGAND PHARMACEUTICALS (LGND) is 6 / 10.